Literature DB >> 17576731

Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.

J Nossent1, N Cikes, E Kiss, A Marchesoni, V Nassonova, M Mosca, M Olesinska, G Pokorny, B Rozman, M Schneider, P G Vlachoyiannopoulos, A Swaak.   

Abstract

Current therapeutic and diagnostic resources have turned systemic lupus erythematosus (SLE) into a chronic disease by reducing mortality rates. The exact contribution of disease activity and disease related damage to mortality is not well studied. The aim of this study was to describe the current causes of death (COD) in a multinational European cohort of patients with SLE in relation to quantified measures of disease activity and damage. Prospective five-year observational study of case fatalities in SLE patients at 12 European centres was performed. Demographics, disease manifestations, interventions and quantified disease activity (by ECLAM and SLEDAI) and damage (by SLICC-DI) at the time of death were related to the various COD. Ninety-one case fatalities (89% females) occurred after median disease duration of 10.2 years (range 0.2-40) corresponding to a annual case fatality of one for each of the participating cohorts. Cumulative mortality correlated linearly with disease duration with nearly 10% of fatalities occurring in the first year and 40% after more than 10 years of disease. Death occurred during SLE remission in one third of cases. In the remaining cases a mixture of disease activity (median ECLAM 5.5, median SLEDAI 15) and accrued damage (median SLICC-DI 5.0) with opposing relationships to disease duration contributed to death. Infections and cardiovascular events were the most frequent COD in both early and late fatalities with no gender differences for type of COD, disease activity, damage or comorbidity. In Europe, case fatalities have become uncommon events in dedicated SLE cohorts. The bimodal mortality curve has flattened out and deaths now occur evenly throughout the disease course with infectious and cardiovascular complications as the main direct COD in both early and late fatalities. Accrued damage supplants disease activity over time as the main SLE specific contributor to death over time.

Entities:  

Mesh:

Year:  2007        PMID: 17576731     DOI: 10.1177/0961203307077987

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  57 in total

Review 1.  Overview of therapeutic applications of non-invasive vagus nerve stimulation: a motivation for novel treatments for systemic lupus erythematosus.

Authors:  Charrise M Ramkissoon; Amparo Güemes; Josep Vehi
Journal:  Bioelectron Med       Date:  2021-05-25

2.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

3.  The development of pulmonary aspergillosis and pneumothorax in a patient with neutropenic systemic lupus erythematosus and successful treatment of the first case.

Authors:  Omer Nuri Pamuk; Gulsum Emel Pamuk; Ebru Barutcu; Aygul Dogan Celik
Journal:  BMJ Case Rep       Date:  2014-05-21

Review 4.  Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.

Authors:  Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

5.  Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Authors:  Ashley J Wilhelm; Amy S Major
Journal:  Int J Clin Rheumtol       Date:  2012-10-01

Review 6.  Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis.

Authors:  Karen Au; Manjit K Singh; Vijay Bodukam; Sangmee Bae; Paul Maranian; Rikke Ogawa; Brennan Spiegel; Maureen McMahon; Bevra Hahn; Dinesh Khanna
Journal:  Arthritis Rheum       Date:  2011-07

7.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

Review 8.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

9.  Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study.

Authors:  Carlos A Roldan; Joseph Joson; Janeen Sharrar; Clifford R Qualls; Wilmer L Sibbitt
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

10.  Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.

Authors:  Z Zhang; L Song; K Maurer; M A Petri; K E Sullivan
Journal:  Genes Immun       Date:  2009-08-27       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.